Lilly completes acquisition of AtaiBeckley

Lilly announced on September 11, 2026 that it had completed its acquisition of AtaiBeckley, after the target's shareholders approved the transaction. The deal was announced in July at up to $3.8 billion in cash. The completed deal gives Lilly control of BPL-003 for treatment-resistant depression, with Phase 3 results expected around 2029.

• Acquisition completed September 11, 2026
• Deal value up to $3.8B, including the CVR
• AtaiBeckley shareholders approved the transaction
• Lead asset BPL-003 Phase 3 results expected around 2029